Incorporating Genomic Testing For Prostate Cancer into Your Practice Webcast (2021)
There are multiple genomic tests currently available for men with localized prostate cancer. The outcomes of these tests may lead to different treatment decisions (active surveillance, surgery, radiation, etc) or impact the frequency of monitoring. The availability and marketing of genomic testing has outpaced a reflective, evidence based medicine approach to using these tests. Discussing the research studies that led to the approval of the various genomic tests, understanding the prognostic clinical endpoints they predict, reviewing current AUA and NCCN guidelines for prostate cancer genomic testing, and examining available validation studies will provide participants with the knowledge to assess these tests and apply them to their clinical practice.
ACKNOWLEDGEMENTS
Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme.
Target Audience
- Urologists
- Residents
- Advanced Practice Providers (Nurse Practitioners and Physician Assistants)
Learning Objectives
At the conclusion of the activity, participants will be able to:
- Describe the seminal validation studies for prostate cancer genomic testing.
- List the different prognostic endpoints provided by various genomic tests.
- Identify appropriate genomic testing based on a patient's unique clinical characteristics.
- Review the AUA and NCCN guidelines for genomic testing for prostate cancer.
Education Council Disclosures
Education Council Disclosures 2021
COI Review Work Group Disclosures
COI Review Work Group Disclosures 2021
All relevant financial relationships have been mitigated.
AUA Office of Education Staff has nothing to disclose.
Joseph Wagner, MD
Matthew Cooperberg, MD
Daniel Lin, MD
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by viewing the webcast and/or listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 2.00 hours
Release Date: May, 2021
Expiration Date: March, 2022
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation